Member Info for Rockefellow

Https://puretechhealth.com/images/PRTCCorpPresentation.pdf

Puretech is in play.Tang likely to force a sales process.watch this space.

Likely.Thats when we get action.

Https://kvgo.com/rbc-2025-cm-healthcare-private-company-conference/seaport-therapeutics-inc-december

There is Seaport IPO to look forward to.There could be multiple licensing deal for the Glyph platform.

Great summary.Robert Lyne is on the case I’m sure.

Https://www.fiercepharma.com/m-a/roche-ready-to-roll-on-intermune-s-lung-drug-8-6b-buyout-deal

Is a very attractive for Big Pharma on the prowl for late stage assets.Expect considerable interest.

Seller still there…

2. Strengthen our engagement with UK capital markets through continued focus on our LSE listing: We view our presence on the London Stock Exchange as an important part of our history and identity. PureTech has always internally developed - and therefore offered UK investors differentiated access to - some of the most innovative biopharmaceutical advances globally, including high-conviction programs like KarXT and deupirfenidone, alongside balance sheet strength and the potential for future capital returns. To further deepen this engagement, we will be initiating a search for up to two new independent non-executive directors to include relevant UK capital markets expertise.

Board has already make the decision to focus on the UK.

Only Peel Hunt are covering atm with a target of 520p.Still nothing from UBS and other brokers that were planning to cover.

Seaport news https://seaporttx.com/press-release/seaport-therapeutics-presents-data-further-validating-glyphtm-platforms-ability-to-enhance-oral-bioavailability-and-expand-therapeutic-reach/

With 35pc plus milestones and royalties of Seaport in for free!

Gallop needs a partner(s) to pump in $100m plus .then there is likely to be a Nasdaq listing.

Latest presentation https://puretechhealth.com/images/PRTCCorpPresentation.pdf

News of the design and protocols for LYT100 phase three trial for IPF must be imminent.

Https://www.grandviewresearch.com/industry-analysis/acute-myeloid-leukemia-therapeutics-market

A FTSE 100 candidate in coming years

With £200m cash.i go for £2.5bn by end of 2026 £10 a share.